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Abstract 
 
Activation of the p53 pathway in adipose tissue contributes to insulin resistance associated 
with obesity. However, the mechanisms of p53 activation and the impact on adipocyte 
functions are still elusive. Here we found a higher level of DNA oxidation and a reduction in 
telomere length in adipose tissue of high-fat diet mice and an increase in DNA damage and 
activation of the p53 pathway in adipocytes. Interestingly, hallmarks of chronic DNA damage 
are visible at the onset of obesity. Furthermore, treatment of lean mice with doxorubicin, a 
DNA damage-inducing drug, increased the expression of chemokines in adipose tissue and 
promoted its infiltration by pro-inflammatory macrophages and neutrophils together with 
adipocyte insulin resistance. In vitro, DNA damage in adipocytes increased chemokines 
expression and triggered the production of chemotactic factors for macrophages and 
neutrophils. Insulin signaling and effect on glucose uptake and Glut4 translocation were 
decreased while lipolysis was increased. These events were prevented by p53 inhibition 
whereas its activation by nutlin-3 reproduced the DNA damage-induced adverse effects. This 
study reveals that DNA damage in obese adipocyte could trigger p53-dependent signals 
involved in alteration of adipocyte metabolism and secretory function leading to adipose 
tissue inflammation, adipocyte dysfunction and insulin resistance.   
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Insulin resistance is associated with obesity and is a major risk factor for type 2 diabetes. 
Adipose tissue (AT) plays an important role in the glucose and lipid homeostasis (1,2) and AT 
dysfunction associated with obesity has emerged as a critical event for the development of 
insulin resistance. Both low grade inflammation and oxidative and hypoxic stresses develop in 
obese AT and are involved in the alteration of adipocyte functions (3-6). Therefore, activation 
of stress signaling pathways in adipocytes are critically involved in AT dysfunction and 
insulin resistance (7-10). 
The tumor suppressor p53 has recently emerged as a novel regulator of metabolic homeostasis 
and adaptation to nutritional changes in different organs including AT (11-13). Thus, a role 
for the alterations of p53 activation has been proposed in metabolic diseases such as diabetes 
and obesity. Indeed, activation of p53 was reported in AT of genetically and high-fat/high-
sugar obese mice (14,15) and it was shown that invalidation of p53 in adipocyte protects 
obese mice from insulin resistance and reduces AT inflammation (15). Conversely, p53 
overexpression in adipocyte triggers insulin resistance and the expression of pro-
inflammatory cytokines in the AT (15). Despite the significance of p53 activation in obese 
AT, its role in the alterations of adipocyte functions and the causes of its activation in obese 
AT are poorly understood.  
The p53 pathway is a key effector of the DNA damage response (DDR) and is activated by 
several stressors that induce DNA lesions, the most deleterious one being DNA double-strand 
breaks (DSBs) (16). The oxidative stress occurring in AT of obese subjects is among the 
several possible stressors (4,15). We thus hypothesized that nuclear DNA damage in 
adipocytes triggers the activation of the p53 pathway leading to metabolic and endocrine 
dysfunctions in adipocyte and to systemic propagation of deleterious signals for insulin 
sensitivity. 
Research Design and Methods  
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Cell culture 
Human visceral preadipocytes from lean non-diabetic subjects (Biopredic, Rennes, France)  
and 3T3-L1 cells were differentiated into adipocytes as described (17,18). siRNA 
(Dharmacon) transfection was performed with INTERFERin
TM
 (Ozyme, St Quentin-en -
Yvelines, France) as in (19). Raw 264.7 and Raw-blue
TM
 (InvivoGen) macrophages are 
maintained in DMEM-5% heat-inactivated FCS. Raw-blue
TM
 expressed the secreted 
embryonic alkaline phosphatase (SEAP) under the control of NF-κB and AP-1. Human 
mononucleated cells were isolated from blood using Ficoll Hypaque and monocytes were 
enriched and differentiated into M0 macrophages as in (20). Volunteers signed an informed 
consent according to the Declaration of Helsinki and recommendations of an independent 
scientific review board. 
Animal studies  
Male mice were purchased from Charles Rivers Laboratory (St-Aubin-lès-Elbeuf, France). 
Ob/ob and ob/+ mice were used at 14 weeks of age. C57BL6/J mice were used for high-fat 
diets experiments (45 or 60 kcal% fat, SSNIFF, Soest, Germany) started at 7 weeks of age and 
continued for 2, 4, or 18 weeks (see Supplementary Table 1). 15 weeks-old C57BL/6J mice 
were injected for 42 h with doxorubicin (2mg/kg, Sigma-Aldrich) or 0.9 % NaCl for epiAT 
analysis.  Intraperitoneal Glucose Tolerance Test (IPGTT) was performed as described (21) 
after starvation for 6 h. The Animal Care Committee of the Nice/Sophia-Antipolis University 
approved all studies. 
Measurement of insulin signaling and metabolism in adipocytes  
Insulin signaling, 2-[
3
H]-deoxyglucose uptake, Glut4 translocation and lipogenesis on isolated 
adipocytes were determined as described (22). Glycerol content in the medium was 
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determined as read out of adipocyte lipolysis using the GPO-Trinder-colorimetric assay 
(Sigma).  
Flow cytometry analysis of AT immune cells 
The stroma vascular faction (SVF) cells obtained after epiAT treatment with collagenase (21) 
was incubated 15 min with Fc block, resuspended in dedicated buffer and stained for 30 min 
at 4 °C with fluorochrome-conjugated specific antibodies or control isotypes to quantify 
macrophages (F4/80 and CD11c), neutrophils (Lys6G and CD11b), T (CD3) or B (B220) 
lymphocytes. The labeling was analyzed by flow cytometry using a MACSQuant cytometer 
(Miltenyi) and the FlowJo software (TreeStar).  
Immune cells chemotaxis and activation assays 
Chemotaxis of RAW 264.7 and human M0 macrophages induced by adipocyte conditioned 
media (AdCM) was assessed by Boyden chambers assay (8-µm pores, BD Bioscience). Cells 
that are migrated at the filter lower face were labeled with Crystal Violet and counted in five 
randomly selected areas. For macrophage activation SEAP activity was quantified in the 
media of Raw-blue
TM
 cells. RNAs were prepared for the analysis of polarization marker 
expression. Human M0 polarization was determined by the quantification of the surface 
expression of M0, M1, and M2 markers as described (20). 
To quantify neutrophil migration against AdCM, 2x10
5
 white blood cells were plated in the 
upper chamber of Boyden chambers (3-µm pores). 2 h later, cells in the lower chamber were 
labeled with FITC-coupled Lys6G and PE-coupled CD11b antibodies before flow cytometry 
analysis.    
Immunofluorescence studies 
Snap-frozen epiAT was embedded in Optimal-Cutting-Temperature medium. 15-µm sections 
were fixed in 4% PFA, incubated in 10 mM glycine, washed, and incubated in PBS/2% 
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BSA/0.1% Tween-20. Adipocytes from epiAT were isolated by collagenase digestion as 
described (21) and were fixed as above. The AT sections or isolated adipocytes were then 
incubated with the indicated antibodies and DAPI, washed, and mounted. Images were 
quantified using Motion-tracking software (23).  
3Disco tissue clearing method (24) was adapted to AT. EpiAT was fixed in 3% PFA and 
successively washed in PBS containing either 0.2% Triton X-100, or 0.2% Triton X-100/20% 
DMSO, or 0.1% Tween-20/0.1% Triton X-100/0.1% deoxycholate/0.1% NP40/20% DMSO 
for 24 h each. EpiAT was then incubated overnight in PBS/0.2% Triton X-100/10% 
DMSO/0.3 M glycine and blocked by adding 6% BSA for 2 days. After 2 washes in PTwH 
(PBS/0.2% Tween-20/0.001% heparin), samples were incubated two days with FITC-labeled 
anti-γ-H2AX antibody, alexa647-phalloidin and DAPI in PTwH/5% DMSO/3% BSA and 
washed in PTwH for two extra days. The clearing was performed by successively using 50%, 
75%, and 100% tetrahydrofuran 3h each time and finally with dibenzyl-ether for 2h before 
confocal acquisition and image analysis with FiJi software.  
Microarray analysis 
RNA was isolated from 3T3-L1 adipocytes using RNeasy Lipid Tissue Kit (Qiagen), 
quantified by a NanoDrop ND-1000, and their quality verified with an Agilent 2100. cRNA 
were prepared using TargetAmp Nano-g Biotin-aRNA Labeling for Illumina System 
(Epicentre) and hybridized to Illumina Mouse WG-6 v2.0 Beadarrays. Microarray data were 
normalized and analyzed using the Limma package of the R software (25). We performed a 
background correction using negative controls on the raw data, we applied a quantile 
normalization using positive controls followed by a log2 transformation, and we applied a 1% 
threshold on the detection p-values, which led to consider 13314 genes as expressed. We 
analyzed the variance (ANOVA) using the “eBayes” procedure of Limma and p-values were 
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corrected for multiple testing using Benjamini and Hochberg’s method to control the false 
discovery rate with a 5% threshold. 
ROS, DNA oxidation and Telomere length determination 
ROS was quantified in 30-µm epiAT sections using DHE as described in (15) or in isolated 
adipocytes using the ROS-probe H2DCFDA (10µM). Adipocytes were recovered by 
centrifugation on dinonylphthalate and resuspended in H2O2 before fluorescence 
measurement. DNA was prepared from snap-frozen epiAT (DNeasy blood & tissue kit, 
Qiagen). 8-hydroxy-2-deoxyguanosine (8-OHdG) amounts were determined using EIA-
dedicated kit (StressMarq Biosciences Inc) using manufacturer’s recommendations. 
Quantitative-PCR was used that compares telomere repeat sequence copy number to single 
copy gene albumin.  
Western Blotting and RT-qPCR 
Cells were lysed and immunoblotting was performed as described (26) using indicated 
antibodies. RNA preparation and qRT-PCR were performed as described (26). Primers were 
from SABiosciences (Qiagen). The PCR data were analyzed with the comparative Ct (∆∆Ct) 
quantitation method. 
Statistical analysis 
Data are expressed as the mean + SEM. Differences among groups were compared using 
ANOVA with post-hoc analysis for multiple comparisons and Mann and Whitney test or 
Student’s t test when there were only two groups. Correlation analysis was done by Spearman 
test. Statistical analyses were performed using GraphPad PRISM 5 software, and the 
differences were considered significant when P <0.05.  
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Results  
The p53 pathway is activated in adipocytes from obese mice 
The p21 mRNA level, a p53-target gene, was higher in epiAT and in the adipocyte fraction of 
the obese ob/ob and high-fat diet (HFD) fed mice compared to their lean counterparts (Fig. 
1A, B). The p21 mRNA level in the adipocyte fraction from ob/ob and HFD-fed mice was 
positively correlated to whole body and fat pad weights and fasting glycemia (Supplementary 
Table 2). Expression of p53 and p21 proteins was higher in adipocytes from HFD-fed 
compared to normal chow diet (NCD) fed mice (Fig. 1C). Moreover, the number of 
adipocytes with a p21-positive nucleus was higher in HFD-fed mice compared to NCD-fed 
mice (61.7 % + 5.50 vs 19.9 % + 4.04, respectively, p < 0.01, Fig. 1D). This supports an 
activation of the p53 pathway in mature obese adipocytes. 
A high-fat diet causes DNA damage in adipocytes which occurs early upon obesity onset  
A main cause for p53 activation is DNA damage such as telomere shortening and/or DNA 
double-strand breaks (DSBs) themselves caused by ROS-induced DNA oxidation. We found 
a 1.5 fold increase in 8-OHdG, a marker of oxidative DNA damage (27), in the epiAT from 
HFD-fed mice for 18 weeks (Fig. 1E) which positively correlated with p21 expression (Fig 
1F) suggesting a link between DNA oxidation and p53 activation. We quantified the number 
of adipocytes with nuclear foci containing phosphorylated histone H2AX (γ-H2AX) which 
positively correlates with DNA damage. The proportion of adipocytes with no γ-H2AX foci, 
meaning without DNA damage, was lower in HFD-fed compared to NCD-fed mice (6% vs 
12%, respectively) (point 0 in Fig. 1I). Furthermore, the proportion of adipocytes with high 
numbers of γ-H2AX foci per nucleus was increased in adipocytes from HFD-fed mice 
(representative image in Fig. 1H and quantification of 80-120 adipocytes per group in Fig. 1I). 
Moreover, we found shortened telomeres in epiAT from HFD-fed mice (Fig. 1G) and 
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telomere length was inversely correlated to p21 expression, whole body and fat pad weights, 
and fasting glycemia (Supplementary Table 2).  
We next asked whether adipocyte DNA damage was an early event upon the onset of obesity 
by studying mice after 2 and 4 weeks of HFD-feeding which increased body weight gain, 
epiAT weight and adipocyte size (Supplementary Fig. 1F-H). Using the 3Disco method, we 
imaged the whole epiAT and characterized cell types with DNA damage using γ-H2AX 
labeling. Two or four weeks of HFD increased by 2 to 3-fold respectively the number of 
adipocytes with γ-H2AX-positive nuclei (cyan color) (Fig. 2A, B). ROS amounts were 
concomitantly increased both in epiAT and in adipocytes (Fig. 2C). DNA damage was also 
detected in non-adipocyte cells (white color in Fig. 2A). The expression of p53 protein and of 
p21 mRNA was increased together with the expression of p16
INK4A
 and p19
ARF
 mRNA 
encoded by the CDKN2A locus which are hallmarks of chronic DNA damage (Fig. 2D) (28). 
Importantly, after 2 weeks of HFD, we did not observe features of insulin resistance of 
adipocytes since insulin-induced lipogenesis in isolated adipocytes (Fig. 2E) and epiAT 
expression of IRS1 and adiponectin mRNA was not different compared to NCD-fed mice 
while Glut4 mRNA level was increased (Fig. 2F). Leptin mRNA level was increased in 
agreement with the increase in epiAT weight and adipocyte diameter (Fig. 2F, Supplementary 
Fig. 1 A, B). Two weeks of HFD feeding did not markedly alter glucose homeostasis since 
IPGTT indicated similar glucose tolerance (Fig. 2G) with no difference in insulin secretion 
during IPGTT compared to NCD-fed mice (0.89 ng/ml + 0.13 vs 0.84 ng/ml + 0.15, 
respectively). Moreover, 2 weeks of HFD did not modify the insulin resistance index 
(HOMA-IR) (Fig. 2H) and the fasting and fed glycemia or insulinemia (Supplementary Fig. 
1C, D). By contrast, mice developed glucose intolerance after 4 weeks of HFD-feeding with a 
further increase in whole body and epiAT weights and adipocyte size as well as a trend 
toward a decrease in IRS1 mRNA (Supplementary Fig. 1A, B, E-I).  
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After two weeks of HFD, we found in epiAT a lower iNOS/Arg ratio, an up-regulation of the 
M2 marker CD206 mRNA, and of the chemokine CCL2 but we did not detect any significant 
differences in the number of F4/80
+
CD11c
-
 macrophages or of pro-inflammatory F4/80
-
CD11c
+
 or F4/80
+
CD11c
+
 cells (Fig. 2I), neutrophils or T and B lymphocytes (Supplementary 
Fig. 1K, L). Furthermore, inflammatory gene expression in epiAT or circulating level of IL-6 
and TNF-α did not significantly differ compared to NCD-fed mice (Fig. 2I). By contrast, 
infiltration of neutrophils in epiAT was observed after 4 weeks of HFD and was detectable 
until 18 weeks (Supplementary Fig. 1 K, L) with a further increase in CCL2 and IL-6 mRNA 
and a trend toward an increase in CD11c mRNA (Supplementary Fig. 1J). 
These observations support that DNA damage and p53 activation occur very early during 
obesity development concomitantly to an increase in adipocyte ROS but before the insulin 
resistance of adipocyte, the inflammation of AT and the glucose intolerance. 
DNA damage causes AT inflammation and adipocyte insulin resistance in vivo 
We next assessed the impact of DNA damage on AT inflammation and adipocyte function by 
treating lean mice with short-term injection of the DNA-damaging drug doxorubicin. The 
weight of epiAT did not differ between control and doxorubicin-treated mice (377.0 mg + 
31.2 vs 348.3 mg + 19.6, respectively) but doxorubicin treatment increased the amount of 
F4/80
+
CD11c
-
 and F4/80
+
CD11c
+
 macrophages as well as F4/80
-
CD11c
+
 dendritic-like cells 
in the epiAT (Fig. 3A). Histological examination revealed an infiltration of polynuclear cells 
in epiAT of doxorubicin-treated mice consisting for 50% of Lys6G
+
 neutrophils without 
difference in adipocyte size (Fig. 3B). These changes in immune cells were associated with an 
increase in inflammatory markers such as p65-NFκB phosphorylation in the SVF (Fig. 3C 
TNF-α, IL-1β, and IL-6 mRNA in epiAT, adipocytes, or SVF (Fig. 3D) and with a decrease 
in anti-inflammatory marker CD206 mRNA with a trend toward a decrease of IL-10 mRNA 
(Fig. 3D). As expected, p53 was activated in the epiAT and adipocytes of doxorubicin-treated 
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mice, as indicated by the increase in p21 (Fig. 3E). Doxorubicin decreased Glut4 mRNA and 
protein, IRS1 and adiponectin mRNA (Fig. 3E, F), and the PKB/Akt phosphorylation in 
adipocytes featuring insulin resistance of adipocytes (Fig. 3F). Accordingly, insulin-induced 
lipogenesis was decreased in isolated adipocytes from doxorubicin-treated mice and 
circulating NEFA level was increased (Fig. 3F, G). These changes in adipocyte functions and 
AT inflammation did not markedly impact on whole body glucose metabolism because the 
IPGGT and insulin secretion during this test were unchanged (Fig. 3H, I).  
Adipocyte-mediated macrophage chemotaxis is increased by doxorubicin-induced DNA 
damage and p53 activation 
Based on the above findings, we hypothesized that DNA damage and activation of p53 in 
adipocytes promote the secretion of chemotactic factors triggering immune cells infiltration in 
AT. We thus investigated in vitro the chemotaxis activity of conditioned media (AdCM) from 
adipocytes treated with doxorubicin to induce DNA damage or with nutlin-3 to activate p53 
pathway. Features of DNA damage such as increased number of γ-H2AX foci and of p21 
expression, stabilization and phosphorylation of p53, were observed in doxorubicin-treated 
3T3-L1 adipocytes (Supplementary Fig. 2A-C). Nutlin-3, an inhibitor of the ubiquitin-ligase 
mdm2 involved in p53 degradation (29) also induced the stabilization and phosphorylation of 
p53 and the induction of p21 without inducing DNA damage (Supplementary Fig. 2A-C). 
AdCM from doxorubicin- or nutlin-3-treated 3T3-L1 adipocytes did not increase the pro-
inflammatory polarization of mouse RAW macrophages or human monocyte-derived 
macrophages (Fig. 4A and Supplementary Fig. 3A, B). Importantly, AdCM from doxorubicin- 
or nutlin-3-treated adipocytes exhibited a higher chemotactic activity toward mouse 
macrophages or human monocyte-derived macrophages compared to AdCM from control 
adipocytes (Fig. 4B, C). Compared to control medium or AdCM from control adipocytes, 
AdCM from doxorubicin or nutlin-3-treated adipocytes also exhibited a higher chemotactic 
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activity towards neutrophil, an effect which is similar or even greater (for doxorubicin 
treatment) than the neutrophil chemotactic factor fMLP (Fig. 4D).  
Microarray analysis of 3T3-L1 adipocytes treated with doxorubicin or nutlin-3 revealed that 
among the expressed chemokines, eleven were deregulated in one or both experimental 
conditions (Fig. 5A). Analysis by qRT-PCR confirmed that doxorubicin and nutlin-3 
increased the mRNA expression of CCL9 (a fibroblast and dendritic cells chemotactic 
protein), CXCL1 (a neutrophil chemotactic protein) and CCL2 while the expression of CCL7 
mRNA, another monocytic chemotactic protein was increased by nutlin-3 only (Fig. 5B, C). 
Doxorubicin and nutlin-3 also induced the expression of IL-6. The silencing of p53 blocked 
the induction by nutlin-3 of all of these mRNAs (Fig.5B) and partly prevented their up-
regulation in response to doxorubicin, except for CXCL1 (Fig. 5C). Since p53 silencing only 
partially reduced p53 expression and activation by doxorubicin (Supplementary Fig. 2C), we 
treated cells with both p53 siRNA and pifithrin-α, an inhibitor of p53 transcriptional activity. 
In this condition, CCL2/9, CXCL1, and IL-6 mRNA induction was prevented (Fig. 5C). 
Importantly, we found that the expression of mRNAs coding for CCL2/7/9 and CXCL1 was 
increased in epiAT from doxorubicin-treated, both in the adipocyte and SVF fractions for 
CCL2/7 and only in the adipocyte fraction for CCL9 and CXCL1 (Fig. 5D). We also 
examined the expression of these chemokines at the onset of obesity when DNA damage was 
observed in adipocytes. CCL2 mRNA level was increased after 2 weeks of HFD-feeding (Fig. 
2I) and a trend toward an increase for CCL9 mRNA was observed (Fig. 5E). The mRNA 
levels of all of these chemokines were significantly increased after 4 weeks of HFD-feeding 
(Fig. 5F and Supplementary Fig. 1J).  
DNA damage and p53 activation inhibit insulin signaling and insulin-induced glucose 
transport and increase lipolysis in adipocytes 
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We next assessed whether the insulin resistance of adipocytes from doxorubicin-treated mice 
(Fig. 3) was only the consequences of AT inflammation, or might also be due to an adipocyte 
cell-autonomous effect of DNA damage and p53 activation. Treatment of 3T3-L1 adipocytes 
with doxorubicin or nutlin-3 reduced insulin-induced glucose uptake (Fig. 6A, B) and Glut4 
translocation (Fig. 6E, F) without changing Glut1 and Glut4 expression (Fig. 6C, D). Similar 
results were obtained in human adipocytes (Supplementary Fig. 4A, B). This effect was 
associated with a decrease in insulin signaling in 3T3-L1 and human adipocytes (Fig. 7A, B 
and Supplementary Fig. 4C, D). The insulin-induced PKB/Akt phosphorylation in 3T3-L1 
adipocytes treated with doxorubicin or nutlin-3 was improved by p53 silencing which 
partially reduced p53 expression (Supplementary Fig. 5A) or by treatment with pifithrin-
α (not shown) and fully restored when p53 expression and activity was reduced by using both 
p53 siRNA and pifithrin-α (Fig. 7D, E and supplementary Fig. 5B). It was unlikely that the 
deleterious effects of doxorubicin and nutlin-3 involved secretory factors since treatment of 
adipocytes with AdCM from doxorubicin- or nutlin-3-treated 3T3-L1 adipocytes did not alter 
insulin-induced PKB/Akt phosphorylation (Fig. 7C). 
An increase in lipolysis contributes to AT inflammation and to the alteration in insulin 
sensitivity (30). We found that doxorubicin or nutlin-3 increased lipolysis in 3T3-L1 and 
human adipocytes as evidenced by an increase in glycerol release (Fig. 8A, B and 
Supplementary Fig. 4E, F). The p53 silencing in 3T3-L1 adipocytes decreased by 50 % the 
nutlin-3-induced lipolysis (Fig. 8A). The lipolytic effect of doxorubicin was modestly but 
significantly reduced by p53 silencing and markedly inhibited by using both p53 siRNA and 
pifithrin-α (Fig. 8B). Pifithrin-α alone inhibits by 63.7 % + 6.8 and 34.8 % + 3.3 nutlin-3- and 
doxorubicin-induced lipolysis, respectively.  
To further explore the mechanisms of the lipolytic effect of DNA damage and p53 activation, 
we examined the expression of the lipolytic enzymes and/or of lipid droplet components. 
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Microarray analysis revealed that genes involved in the maintenance of the lipid droplet 
integrity and the repression of basal lipolysis such as PLIN1 (coding for perilipin 1) and 
CIDEC (31,32) were down-regulated in both doxorubicin- or nutlin-treated 3T3-L1 
adipocytes (Fig. 8C). The protein level of perilipin 1 was decreased in adipocytes treated with 
doxorubicin or nutlin-3 (Fig. 8D).  
 
Discussion  
Previous studies have reported an up-regulation of the p53 pathway in AT of obese rodents 
and patients (14,15,33) but the causes of p53 activation in obese adipocytes and its 
consequences on adipocyte metabolism remain ill-defined. Here, we show with several 
image-based approaches an increased in DNA damage in adipocytes not only when obesity 
was established but early upon the onset of obesity before alterations in adipocyte insulin 
sensitivity and whole-body glucose homeostasis. In addition to adipocytes, other cell types 
that remain to be characterized also had DNA damage. Some of them aligned in branched 
actin-rich structures could be endothelial cells in which p53 was activated in obesity (34). 
Taking into account the high number of γ-H2AX foci per nuclei compared to telomere 
number in the adipocytes from mice with installed obesity, it is likely that both DSBs and 
telomere shortening occurred. DNA damage may thus contribute to p53 stabilization and p21 
up-regulation we observed in adipocytes from HFD-fed mice. Of note, those adipocytes were 
not apoptotic possibly because the induction of p21 protected them from apoptosis (35). 
What could be the cause of adipocyte DNA damage? DNA is sensitive to damage induced by 
oxidative stress and we indeed detected an increase in 8-OHdG level, the most common 
oxidative DNA lesions (36), in AT from obese mice. These oxidative DNA lesions may 
contribute to p53 activation in obese adipocyte because we found a positive correlation 
between 8-OHdG amounts and the expression of the p53-target p21. In installed obesity, both 
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adipocytes and pro-inflammatory macrophages may contribute to the increase in ROS 
production (37,38) that could induce DNA damage in adipocytes and other AT cells. 
However, we also observed DNA damage and ROS in adipocytes at the onset of obesity 
before any increase in pro-inflammatory macrophages or pro-inflammatory cytokines and 
before alterations in whole-body glucose homeostasis and adipocyte insulin sensitivity. This 
increase in ROS may induce DNA damage and consequently activation of the DDR known to 
induce innate inflammatory response (39) and thus could be causal factors in obese AT 
inflammation and adipocyte dysfunctions.   
Such a link between adipocyte DNA damage, AT inflammation and insulin resistance of 
adipocytes is supported by the increased amount of pro-inflammatory immune cells in the AT 
and the adipocyte insulin resistance of lean mice treated with the DNA damage-inducing drug 
doxorubicin. Our data argue that these changes in AT immune cells are the consequence of 
p53-dependent secretion of chemokines induced by DNA damage in the adipocytes. 
Importantly, the changes in immune cells populations and in chemokine expression in AT of 
doxorubicin-treated mice is at least qualitatively consistent with those described in obesity 
(40,41). Therefore, DNA damage in adipocyte may trigger macrophages and neutrophils 
recruitment within AT through the p53-dependent production of several chemokines. Because 
the secretome from adipocytes treated in vitro with doxorubicin did not promote macrophage 
polarization, the increase in pro-inflammatory macrophages in AT from doxorubicin-treated 
mice would either be due to DNA damage in other cell types or to the vicious cycle that takes 
place between adipocytes and macrophages leading to macrophage activation (42). Also, 
other adipocyte p53-dependent mechanisms could contribute to AT inflammation during 
obesity (43).  
Hence, DNA damage by increasing AT inflammation may promote adipocyte insulin 
resistance and dysfunction. However, DNA damage may also trigger adipocyte insulin 
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resistance independently of AT inflammation since inducing DNA damage in cultured 
adipocyte decreased insulin signaling and uptake of glucose and increased lipolysis. This is 
not due to a paracrine action of adipocyte-secreted factors. It is thus plausible that the DDR, 
mainly through p53 activation, promotes transcription of proteins down-regulating insulin 
signaling that remains to be identified but it was unlikely that MAP kinases were involved 
because they were not activated in our settings (data not shown). Based on our findings, it is 
tempting to speculate that DNA damage by altering adipocyte functions contributes to 
systemic insulin resistance. Indeed, by decreasing glucose flux, DNA damage may reduce de 
novo lipogenesis and such decrease is associated with reduced insulin sensitivity  (44-46) 
whereas DNA damage increases lipolysis which is positively correlated with insulin 
resistance (30).  
In summary, our study shows that DNA damage occurs early in the adipocytes at the onset of 
obesity and before the development of AT inflammation and adipocyte insulin resistance. 
DNA damage in adipocyte may be thus causal in the dysfunction and inflammation of AT 
(Supplementary Fig. 6). Pharmacological or nutritional strategies preventing DNA damage in 
adipocytes may thus be beneficial for the metabolic complications of obesity. 
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Figure legends 
Figure 1. Adipocytes of obese mice exhibit activation of the p53 pathway with an 
increase in DNA damage and a reduction in telomere length.  
Level of p21 mRNA in epididymal adipose tissue (AT) and isolated adipocytes (Ad) of ob/ob 
(A) and HFD mice (18 weeks of 60% kcal from fat)  (B) and their lean control littermates 
(n=8 per group).  p21 mRNA expression was normalized using mouse Rplp0 mRNA level 
and expressed in arbitrary units with the control value (ob/+ or normal chow diet NCD mice) 
taken as 1. C: Western blot analysis of the expression p53 (anti-p53 #2524, Cell Signaling) 
and p21 (anti-p21, clone CP74, P1484, Sigma-Aldrich) in isolated adipocytes from HFD and 
NCD fed mice with tubulin (anti-tubulin T6199, Sigma-Aldrich) as loading control. Each lane 
corresponds to independent preparations of adipocytes. D: Immunofluorescence analysis of 
p21 in nucleus of isolated adipocytes from HFD and NCD mice. DAPI was used to visualize 
the nuclei. Representative images and quantification of nuclei with detectable p21 labeling in 
15-20 cells per adipocyte preparation (n=8) were shown. E: Amounts of 8-OHdG quantified 
in total DNA from AT of mice fed a NCD or a HFD (45% or 60% of kcalories from fat, n=8 
per group). Results are expressed in pg of oxidized dG per µg of AT DNA. F: Correlation 
between amounts of AT oxidized DNA and AT p21 mRNA expression. Red dots: NCD-fed 
mice, blue dots: 45 % HFD fed mice, black dots:  60% HFD fed mice.  G:  Relative telomere 
length was estimated from total DNA prepared from AT of NCD and HFD mice (n=8 per 
group). Results are expressed in arbitrary units with the NCD mice taken as 1. H and I: 
Isolated adipocytes from NCD and HFD mice (60 % kcal from fat) were treated for 
immunofluorescence as in (D). Immunodetection was performed with anti γH2AX (Ser139) 
antibodies (Millipore 05-636) followed by anti-mouse antibodies coupled to AlexaFluor488. 
Nuclei were labeled by DAPI. The quantifications of the foci number were performed on 10-
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15 cells per adipocytes preparations (n=8 per group) and the graph represents the number of 
cells as a function of the foci number.  
Data are means + SEM with * p < 0.05, ** p < 0.01, *** p < 0.001.  
Figure 2. DNA damage in the adipocyte is an early event during obesity development. 
A: representative images of cleared adipose tissues from NCD-fed and HFD-fed mice (HFD 
feeding for 2 or 4 weeks) labeled with γ-H2AX antibodies (green), DAPI (blue), phalloïdin 
(red) together with enlarged views of the delineated regions. Images were acquired with a 
NikonA1 confocal with a 20x long-working-distance objective, allowing for acquisitions up 
to 3 mm into the tissue.  A mosaic of 9 images over 1 mm was randomly acquired and blindly 
quantified. Z-projections along the z-axis were generated and the DAPI (blue) and phalloidin 
(red) images were merged to discriminate nuclei from small cells that were entirely 
surrounded by F-actin (purple nuclei) from nuclei of mature adipocytes that were not 
surrounded by F-actin (blue nuclei). Adipocyte nuclei without DNA damage are blue (only 
DAPI labeling, arrows). They are cyan when DNA damage was present (merge of DAPI-blue 
and γ-H2AX -green, arrow heads). Nuclei from other smaller cells without DNA damage are 
purple (merge of DAPI-blue and phalloïdin-red) and are white with DNA damage (merge of 
DAPI-blue, γ-H2AX antibodies-green, and phalloïdin-red). B: Quantification of the number 
of adipocytes presenting DNA damage in their nucleus using the colocalization pluging of 
FiJi. Data are expressed as the % of cells with DNA damage and are means + SEM with ** p 
< 0.01, *** p < 0.001 HFD versus NCD mice and 
### 
p < 0.001 HFD 4 weeks versus HFD 2 
weeks. C: Left panel, quantification of ROS using DHE labeling on AT sections from mice 
fed a NCD or a HFD for 2 weeks and 4 weeks; Right panel, quantification of ROS production 
by isolated adipocytes from mice fed a NCD or a HFD for 2 weeks using the ROS probe 
H2DCFDA. Data are means + SEM with *p < 0.05, **p < 0.01, ***p < 0.001 versus NCD 
mice. D: Western blot analysis of the expression of p53 (n=3 representative mice per group) 
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and quantification of p53 protein expression in AT after NCD or HFD feeding for 2 weeks 
(n=13 per group) or 4 weeks (n=5 for NCD and 6 for HFD). Right panel: quantification of the 
indicated mRNA in AT after NCD or HFD feeding for 2 weeks (n=7 mice per group). Results 
are expressed relative to the NCD-fed mice. Data are means + SEM with * p < 0.05, ** p < 
0.01, *** p < 0.001. E: Insulin effect on lipogenesis in isolated adipocytes from mice fed a 
NCD or HFD for 2 weeks (n=6 adipocyte preparations from 6 different mice in each of the 
groups). Data are expressed as fold increase over unstimulated cells. F: quantification of the 
mRNA levels of the indicated genes in AT from mice fed a NCD or HFD during 2 weeks 
(n=7 mice per group). Data are means + SEM with ** p < 0.01. G: IPGTT in mice fed a NCD 
or HFD during 2 weeks. Area under the curve (AUC) was calculated from 0 to 120 min. H: 
HOMA-IR index (fasting glucose mM x fasting insulin µU/ml/22.5) of the same mice as in G. 
I: Left panel, quantification by flow cytometry analysis of the numbers of F4/80
+
 (CD11c
+
 or 
CD11c
-
) and F4/80
-
CD11c
+
 cells in the SVF from mice fed a NCD or a HFD during 2 weeks 
(n=6 mice per group). Values represent the number + SEM of each of the cell subtypes per 
gram of epididymal fat tissues. Fluorescent-coupled anti F4/80 and CD11c were from 
eBioscience. Middle panel, quantification of the mRNA expression of markers of 
inflammation in AT of the same mice. Right panel, concentration of IL-6 and TNF-α  in sera 
of mice fed a NCD or HFD for 2 or 18 weeks (as a positive control). Data are means + SEM 
with * p < 0.05, ** p < 0.01, ***p < 0.01 HFD versus NCD 2 weeks and 
#
 p < 0.05, 
##
p < 0.01 
HFD 18 weeks versus NCD 18 weeks. 
Figure 3. In vivo doxorubicin treatment induces AT inflammation and adipocyte insulin 
resistance.  
Mice were injected with doxorubicin (doxo) or vehicle (ctrl, n=6 per group) for 42 h before 
analysis of the adipose tissue (AT), the adipocytes (Ad), and the stroma vascular fraction 
(SVF). A: Quantification by flow cytometry analysis of the number of F4/80
+
 (CD11c
+
 or 
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CD11c
-
) and F4/80
-
CD11c
+
 cells in the SVF from control or doxorubicin-treated mice. Values 
represent the number + SEM of each of the cell subtypes per gram of epididymal fat tissues. 
B: Frozen sections of AT were subjected to Hematoxylin/Eosin (H/E) coloration (top) and to 
immunodetection (bottom) with a FITC-coupled anti-Lys6G antibody (Biolegends) and nuclei 
were labeled using DAPI. A representative image from a control and a doxorubicin-treated 
mouse was shown. For quantification, 5 images/mouse were automatically captured and the 
percentage of cells positive for Lys6G was determined. C: Western blot analysis of the level 
of phospho-p65-NFκB (anti-p-p65 NFκB #3033, Cell Signaling) in the SVF from control or 
doxorubicin-treated mice with Rho-GDI as loading control (anti Rho-GDI A20 sc-360, Santa 
Cruz). Each lane corresponds to independent mice. D-E: Relative expression of the indicated 
mRNAs in AT, adipocytes (Ad), and the stroma vascular fraction (SVF) from control and 
doxorubicin-treated mice mice. The mRNA expression was normalized using mouse Rplp0 
mRNA level and expressed in arbitrary units with the control mice taken as 1. AdipoQ is for 
adiponectin. F: Left panel, insulin effect on lipogenesis in isolated adipocytes from control or 
doxorubicin-treated mice (n=4 adipocyte preparations from 4 different mice in each of the 
groups). Data are expressed as fold over unstimulated cells. Right panel, western blot analysis 
of the expression of p-PKB (anti-pPKB Ser473 #4058, Cell Signaling), PKB (anti-PKB 
#9272, Cell Signaling), and Glut4 (anti-Glut4 1F8 sc-53566, Santa Cruz) in isolated 
adipocytes from control and doxorubicin-treated mice with Rho-GDI as loading control. G: 
quantification of Free Fatty Acids (FFA) in sera from control and doxorubicin-treated mice 
(NEFA FS kit, DiaSys). H: IPGTT in control and doxorubicin-treated mice. Area under the 
curve (AUC) was calculated from 0 to 120 min. I: Quantification of insulinemia in sera of 
mice before the injection of glucose and 20 min after glucose injection during the IPGTT 
shown in H. Data are means + SEM with * p <0.05, ** p < 0.01, ***p <0.001 versus control 
mice. 
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Figure 4. Impact of adipocytes-p53 activation on macrophage activation and 
macrophage and neutrophil migration.  
A, B, D: 3T3-L1 adipocytes were treated for 48 h with 10 µM nutlin-3 (Enzo Life Sciences) or 
24 h with 0.5 µg/ml doxorubicin (doxo). Then cells were thoroughly rinsed and fresh medium 
was added and the conditioned media (AdCM) were collected for the following 24 h. A: 
RAW-blue
TM 
macrophages were incubated with conditioned media (AdCM) or control culture 
medium (M) for 24 h and the activity of the alkaline phosphatase released in the media was 
quantified as readout of RAW-blue
TM
 activation. LPS (0.5 ng/ml) was added in control 
medium or AdCM as a positive control for macrophage activation. Quantification of 3 
independent experiments normalized to cells treated with control medium is shown and 
expressed as means + SEM. B: Chemotaxis assay was performed with RAW264.7 
macrophages using the indicated conditioned media (AdCM) or control media (M). The 
number of macrophages stained by crystal violet having performed chemotaxis was counted 
by analyzing 10 fields for each experimental condition. A typical field corresponding to each 
of the experimental condition was shown. Results were normalized relative to the number of 
macrophages attracted by control medium (M). Data are means + SEM of 3 independent 
experiments with ** p < 0.01 control medium versus control AdCM (AdCM from untreated 
adipocytes). 
#
 p < 0.05, 
###
 p < 0.001 AdCM from adipocytes treated with drugs versus control 
AdCM. C: Human cultured adipocytes were treated for 48 h with 10 µM nutlin-3 or 24 h with 
0.75 µg/ml doxorubicin (doxo). Conditioned media (AdCM) were collected as described 
above. Chemotaxis assay was performed with blood monocyte-derived macrophages using the 
indicated AdCM. Results were normalized relative to the number of macrophages attracted by 
control AdCM. Data are means + SEM of 3 experiments with 3 AdCM collected from 3 
independent cultures of human adipocytes with the same human monocyte-derived 
macrophage preparation. * p < 0.05 versus control AdCM. D: The number of neutrophils 
Page 27 of 50 Diabetes
27 
 
having performed chemotaxis towards media (M), fMLP (0.2 µM a chemotactic factor for 
neutrophils), AdCM of control, nutlin, or doxorubicin-treated adipocytes was determined by 
quantifying the number of CD11b
+
Lys6G
+
 cells in the lower Boyden chamber by flow 
cytometry analysis. Top, representative flow cytometry plots for CD11b
+
Lys6G
+
 cells that 
have migrated towards AdCM from control, nutlin, or doxorubicin-treated cells. Bottom, 
quantification of the number of migrating neutrophils in chemotaxis assays performed with 4 
independent AdCM and one white blood cell preparation. The experiment was reproduced 
twice. *p < 0.05, **p < 0.01, ***p < 0.001 versus control AdCM.  
Figure 5. Effect of DNA damage and p53 activation on cytokines/chemokines mRNA 
expression and the implication of p53.  
A: 3T3-L1 adipocytes were treated with 0.5 µg/ml doxorubicin (doxo) for 24 h or 10 µM 
nutlin-3 (nutl) for 48 h. Total RNA were then prepared and used in gene expression profiling 
by microarray. The figure represents the changes in the level of expression of cytokines and 
chemokines between doxorubicin-treated vs control adipocytes as a function of the changes in 
the level of expression between nutlin-treated vs control adipocytes. Changes are expressed in 
Log2. Only the cytokines/chemokines that have an expression changed in one or the two 
experimental conditions were shown. B and C: Relative mRNA amount of the indicated 
chemokines/cytokines in 3T3-L1 adipocytes transfected with control siRNA (si ctrl) or p53 
siRNA (si p53) and incubated without (ctrl) or with nutlin-3 (B) or doxorubicin (C). When 
indicated, adipocytes transfected with p53 siRNA were also treated with pifithrin-α (pif). 
Data (n=3-4 independent experiments) are normalized using mouse Rplp0 mRNA level and 
expressed as arbitrary units with the value of si ctrl untreated cells taken as 1 (dashed line in 
C).  D: Relative mRNA expression of the indicated chemokines in adipose tissue (AT), 
adipocyte (Ad), and stromal vascular fraction (SVF) of control mice or doxorubicin-treated 
mice. The measurements were performed with the same mRNA samples than those used in 
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Fig. 3D, E. E-F: Relative mRNA expression of the indicated chemokines in adipose tissue 
(AT) of mice fed a normal chow diet (NCD) or high fat diet (HFD) for 2 weeks (E) or 4 
weeks (F). The measurements were performed with the same mRNA samples as in Fig 2F-I 
and supplementary Fig E, F.  
Data are means + SEM with * p <0.05, ** p < 0.01, *** p <0.001 versus effect in untreated si 
ctrl cells or in mice injected with vehicle, or in NCD-fed mice, 
#
 p < 0.05, 
## 
p < 0.01 drug-
treated si ctrl cells versus drug-treated si p53 cells. 
Figure 6. Inhibition of insulin-induced glucose transport and Glut4 translocation in 
adipocytes treated with doxorubicin or nutlin-3.   
3T3-L1 adipocytes were treated with 0.5 µg/ml doxorubicin (doxo) for 24 h or 10 µM nutlin-
3 (nutlin) for 48 h and stimulated with the indicated concentrations of insulin for 10 min. A 
and B:  Measurement of deoxyglucose (DOG) uptake (n=3 independent experiments). C, D: 
Representative Western blot analysis and quantification (n= 4 independent experiments) of 
the protein expression of the glucose transporters Glut4 (anti-Glut4 1F8, Santa Cruz) and 
Glut1 (anti Glut1 ab652, Abcam) with tubulin as loading control. E, F: Glut4 translocation 
was determined by the quantification of Glut4 amount in plasma membrane lawns. 
Quantification of 26 fields obtained in two independent experiments (top panels) and 
representative fields (bottom panels) were shown.  
Data are means + SEM with * p <0.05, * p <0.01, *** p <0.001 untreated cells stimulated 
with insulin versus drug-treated cells stimulated with insulin. 
Figure 7. Inhibition of insulin signaling in 3T3-L1 adipocytes treated with doxorubicin 
or nutlin-3.  
3T3-L1 adipocytes were treated with 0.5 µg/ml doxorubicin for 24 h (doxo) or 10 µM nutlin-
3 (nutlin) for 48 h and incubated without or with insulin (ins, 0.5 nM) for 10 min.  A and B: 
Representative western blot analysis and quantification (n= 3-4 independent experiments) of 
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the expression of the tyrosine phosphorylated (anti-PhosphoTyrosine #9411, Cell Signaling) 
insulin receptor (pY-IR) and IRS (pY-IRS), the pThr308-PKB (p-PKB, anti-pThr308-PKB 
#4056, Cell Signaling), total PKB and p53. Data are expressed as percentage of insulin effect 
in untreated cells stimulated with insulin. Normalization was performed by quantifying ERK 
(anti-ERK1/2 #4695, Cell Signaling) or HSP90 (anti-HSP90 sc-13119, Santa Cruz) in each of 
the experiments. C:  3T3-L1 adipocytes were treated for 24 h with 0.5 µg/ml doxorubicin 
(doxo) or for 48h with nutlin-3 (10 µM) and the conditioned media (AdCM) was collected as 
described in figure 4. 3T3-L1 adipocytes were incubated with AdCM for 24 h, washed and 
incubated without or with insulin (ins, 0.5 nM) for 10 min, before lysis for western blot 
analysis of PKB phosphorylation. Representative immunoblot and quantification of 3 
independent experiments are shown. The ratios of PThr308-PKB (p-PKB) relative to HSP90 
are expressed as percentage of insulin effect in cells treated with control AdCM.  D and E: 
3T3-L1 adipocytes were transfected with control siRNA (si Ctrl) or p53 siRNA (si p53). The 
cells treated with p53 siRNA were also incubated with pifithrin-α (pif, 50 µM).  Cells were 
incubated with 0.5 µg/ml doxorubicin for 24 h (D) or with 10 µM nutlin-3 for 48 h (E). 
Adipocytes were then stimulated with 0.5 nM insulin for 10 min. Western blot analysis of p53 
and p21 expression (left panels) and pThr308-PKB (p-PKB) and total PKB expression (right 
panels) with HSP90 as loading control. Representative immunoblots are shown and 
quantifications are presented in the supplemental figure 5. 
Data are means + SEM with * p < 0.05, ** p < 0.01, *** p < 0.001 untreated cells stimulated 
with insulin versus drug-treated cells stimulated with insulin 
Figure 8. Doxorubicin and nutlin-3 stimulate lipolysis in adipocytes.  
A-B: Glycerol release was measured as an index of lipolysis, in the medium of 3T3-L1 
adipocytes transfected with control siRNA (si ctrl) or p53 siRNA (si p53) and treated with 
nutlin-3 (A) or doxorubicin with or without pifithrin-α (pif) (B). Data are expressed as fold 
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increase over control cells (untreated cells transfected with si ctrl) and are presented as means 
+ SEM of 3-4 independent experiments with *** p < 0.001 untreated si ctrl cells vs drug-
treated si ctrl cells, 
# 
p <0.05, 
## 
p <0.01 drug-treated si ctrl cells vs drug-treated si p53 cells. 
C:  3T3-L1 adipocytes were treated with 0.5 µg/ml doxorubicin (doxo) for 24 h or 10 µM 
nutlin-3 (nutl) for 48 h. Total RNA were then prepared and used in gene expression profiling. 
The figure represents the changes in the level of expression of genes involved in lipolysis 
between doxorubicin-treated vs control adipocytes as a function of the changes in the level of 
expression between nutlin-treated vs control adipocytes. Changes are expressed in Log2. The 
name of genes down-regulated in both doxorubicin and nutlin-treated adipocyte were 
indicated. D: Representative western blot and quantification (n= 3 independent experiments) 
of the expression of perilipin 1 (PLN1 gene) using an anti-perilipin 1 antibody (D418, Cell 
Signaling) with HSP90 as loading control. Data are means + SEM with *p < 0.05 nutlin- or 
doxorubicin-treated cells versus control 
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Online Supplemental Table 1 
Characteristics of the normal-chow fed mice and the high-fat fed mice. 
 Body 
Weight  
(g) 
Fat pads 
Weight  
(mg) 
Fasting 
Glycemia  
(mg/dl) 
IPGTT 
AUC  
(arbitrary unit) 
 
 
Normal chow (n=32)  
 
28.76 + 0.35 
 
605 + 83.25 
 
165.3 + 7. 86 
 
7121 + 1466 
 
high-fat 45 % (n=8) 
high-fat 65 % (n=16) 
 
37.80 + 0.90 *** 
44.31 + 1.54*** 
###
 
2330 + 151.1*** 
2817 + 180.4*** 
 
205.5 + 11.97* 
246.0 + 7.11*** 
# 
 
13734 + 1527** 
18540 + 1171*** 
 
 
Data are means + SEM. Comparison between groups was performed with ANOVA and 
Bonferroni post-hoc test in the case of 18 week-diet. * P< 0.05, ** P< 0.01, *** P< 0.001 
standard chow vs high-fat diet; 
# 
P<0.05, high-fat diet 65 % vs high-fat diet 45 %.  
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Online Supplemental Table 2 
Correlative analysis between telomere length, p21 mRNA expression, obesity, and 
glycemia 
 Body 
weight 
Fat pads 
weight 
Fasting 
glycemia 
p21 mRNA 
level 
 
Telomere length 
 
-0.549 ** 
 
-0.573 ** 
 
-0.533** 
 
-0.430* 
 
p21 mRNA level 
 
0.720 *** 
 
 
0.684 *** 
 
0.494 * 
 
 
Telomere length and p21 mRNA level were measured in adipose tissue from mice fed a 
normal chow-diet (n=8) or a high-fat diet (45 % and 60 % kcal from fat, n=8 for each diet) 
and correlated to each other and to body weight, fat pads weight and fasting glycemia by 
Spearman correlation test. Spearman r was indicated in the table. * P< 0.05, ** P< 0.01 and 
*** P< 0.001.   
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Supplemental figure legends 
Supplemental Figure 1. Characterization of mice fed a high-fat diet for 2 or 4 weeks vs 
mice fed a normal chow diet.  
A: Weight of the epididymal adipose tissue (epiAT).  B: Mean adipocyte diameter (left) and 
adipocyte number distribution relative to their diameter (right).  C: Serum glucose and insulin 
levels in 6 h-fasted mice fed a NCD or a HFD for 2 weeks (n =13 mice per groups analyzed in 
two independent experiments) D: Serum glucose and insulin level in the same mice as in C 
but random fed. E: IPGTT in mice fed a NCD (n=5) or HFD (n=6) for 4 weeks. F: Serum 
glucose and insulin levels in 6 h-fasted mice fed a NCD (n=5) or a HFD (n=6) for 4 weeks. G: 
Serum glucose and insulin level in the same mice as in F but random fed. H: Body weight 
gain of the mice after 2 or 4 weeks of HFD. I-J: Expression of the mRNA expression of the 
indicated genes in AT of mice fed a NCD or HFD for 4 weeks. K: Quantification of 
neutrophil infiltration in AT of mice fed a NCD or HFD for 2, 4, and 18 weeks by 
immunodetection on AT section with anti-Lys6G antibodies as described in Figure 3.  L: 
Quantification of immune cells by flow cytometry in the SVF of AT from mice fed a NCD or 
HFD for 2 weeks. The CD11b and Lys6G were used to quantify neutrophils, CD3 for T 
lymphocytes, and B220 for B lymphocytes. Results are expressed as the number of cells per g 
of epididymal AT.  
Date are means + SEM with * p < 0.05, ** p < 0.01 and *** p < 0.001 versus NCD-fed mice   
Supplemental Figure 2.  Induction of DNA damage by doxorubicin and nutlin-3 and 
effect of p53 siRNA on p53 and p21 expression  
3T3-L1 adipocytes cultured on glass coverslips were treated for 24 h with 0.5 µg/ml of 
doxorubicin or for 48 h with 10 µM nutlin-3. Adipocytes were then treated for 
immunofluorescence for γ-H2AX labeling (A) or p21 labeling (B) and nucleus detection by 
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using DAPI. The bar corresponds to 10 µm. The arrow heads point to p21-labeled nuclei. C: 
Western blot analysis of the expression of the indicated protein in 3T3-L1 adipocytes 
transfected with control siRNA (ctrl) or p53 siRNA and then treated with 10 µM nutlin-3 
(nutlin) or with 0.5 µM of doxorubicin. Hsp90 as loading control. A representative 
experiment was shown.  
Supplemental Figure 3. Conditioned media from doxorubicin or nutlin-3-treated 
adipocytes do not modify macrophages polarization 
A: 3T3-L1 adipocytes were treated for 48 h with 10 µM nutlin-3 (nutlin), 24 h with 0.5 µg/ml 
doxorubicin (doxo), or vehicle (control). Cells were then thoroughly rinsed and fresh medium 
was added and the conditioned media was collected for the following 24 h. RAW-blue
TM 
macrophages were incubated with the conditioned media for 24 h and the RNA were 
extracted in order to quantify the expression of the indicated markers for M1-type and M2-
type macrophages. 6-8 independent conditioned media were incubated with macrophages and 
the results are expressed relative to the mean of the expression of each of the markers in the 
control condition. No significant differences were observed between the three conditions 
(ANOVA test). B: Blood-derived human monocytes were incubated with 100 ng/ml LPS and 
20 ng/ml INF-γ to induce M1 polarization, with 20 ng/ml IL-4 to induce M2 polarization, or 
with 24 h-conditioned medium (CM) from human adipocytes treated with nutlin (10 µM/48 h: 
CM nutlin) or doxorubicin (0.75 µg/ml for 4 h: CM doxo). The expression of the indicated 
surface markers for M0 (in black), M1 (blue), and M2 (green) were determined by flow 
cytometry analysis.  
Supplemental Figure 4. Effect of doxorubicin and/or nutlin-3 in human adipocytes on 
insulin-induced glucose transport, insulin signaling, and lipolysis  
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A-B: Deoxyglucose (DOG) uptake in human adipocytes treated with 0.75 µg/ml doxorubicin 
for 24 h (A) or 10 µM Nutlin for 48 h (B) and stimulated with the indicated concentrations of 
insulin for 10 min. Data represent means + SEM of 3 independent experiments with * p 
<0.05, ** p <0.01, *** p <0.001 control versus nutlin- or doxorubicin-treated cells. C: Human 
adipocytes were treated with 0.75 µg/ml doxorubicin for 24 h and incubated without or with 
insulin (ins, 0.5 nM) for 10 min. Western blot analysis of the expression of the indicated 
protein. Representative immunoblots and means + SEM of 3 independent experiments are 
shown. Normalization was performed by quantifying ERK amount in each of the experiments. 
Data are expressed as percentage of insulin effect in untreated cells stimulated with insulin. 
*** p < 0.001 untreated cells stimulated with insulin vs doxorubicin-treated cells stimulated 
with insulin. D: Human adipocytes were treated with 10 µM nutlin for 48 h and incubated 
without or with insulin (ins, 0.5 nM) for 10 min before western blot analysis of the indicated 
proteins. A presentative immunoblot is shown and experiment was reproduced once with 
similar results. E-F: Glycerol production by human adipocytes treated with 0.75 µg/ml 
doxorubicin for 24 h (C) or 10 µM nutlin-3 for 48 h (D) as an index of lipolysis. Data are 
means + SEM of 3 independent experiments with ** p < 0.01 control versus nutlin- or 
doxorubicin-treated cells 
Supplemental Figure 5. p53 silencing partly prevents the inhibitory action of 
doxorubicin on insulin signaling  
A: Western blot analysis of pThr308-PKB and total PKB in 3T3-L1 adipocytes transfected 
with control siRNA (si Ctrl) or siRNA against p53 (si p53) and incubated without (control) or 
with doxorubicin (doxo, 0.5 µg/ml) or nutlin-3 (10 µM) for 24 h or 48 h respectively before 
insulin stimulation (ins, 0.5 nM) for 10 min. Data are means + SEM of 3 independent 
experiments and are expressed as % of insulin effect in control cells treated with si Ctrl. * p < 
0.05, ** p <0.01, *** p < 0.001 doxorubicin-treated cells versus control cells; 
#
 p < 0.05, 
##
 p 
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< 0.01, si Ctrl doxorubicin-treated cells vs si p53 doxorubicin-treated cells. B:  Quantification 
of the ratio of pThr308-PKB/PKB corresponding to the western blots of Figures 7D and E. 
Graphs represent mean + SEM of 3 independent experiments for doxorubicin and mean + SE 
of 2 independent one for nutlin. ** p <0.01, doxorubicin-treated cells vs control cells.  
Supplemental Figure 6. Schematic representation of the consequences of obesity-induced 
DNA damage in adipocytes.  
ROS production by the AT and adipocytes is increased at the onset of obesity and is 
accompanied by an increase in DNA damage in adipocytes. The induction of DNA damage in 
adipocytes induces adipocyte insulin resistance, an increase in its lypolytic activity, and a 
chemotactic secretome for neutrophil and macrophage. These changes, also observed in obese 
AT, may trigger a deleterious cross-talk between adipocytes and immune cells leading to AT 
inflammation and metabolic dysfunctions.   
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Supplemental figure 3
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